<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00229593</url>
  </required_header>
  <id_info>
    <org_study_id>26852-D</org_study_id>
    <secondary_id>HHSN27500002;</secondary_id>
    <secondary_id>04-3792-D 02</secondary_id>
    <nct_id>NCT00229593</nct_id>
  </id_info>
  <brief_title>NES Gel-1, To Evaluate Nestorone Gel in Combination With Testosterone Gel</brief_title>
  <acronym>NES-1</acronym>
  <official_title>A Randomized, Open Label Clinical Trial to Evaluate if Nestorone Gel Has Gonadotropin Suppressive Activity and if Nestorone in Combination With Testosterone Will Have an Additive Effect on Gonadotropin Suppression When Applied Transdermally in Healthy Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the usefulness of two transdermal gels to be used
      in the future development for a male contraceptive.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The success of hormonal male contraception depends on the near complete suppression of
      spermatogenesis without producing any untoward effects on libido or other androgen-dependent
      functions or any other adverse events. The treatment with androgen alone has geen shown to be
      highly effective in Asian men but less effective in non-Asian men in clinical trials. To
      increase the efficacy of androgen alone treatment on spermatogenesis, combined regimens of a
      progestin and an androgen have shown promising results. The steady-state delivery of a
      progestin and an androgen by transdermal gel application would be a user-friendly delivery
      method as compared to injectable or implant approaches. Nestorone (NES) is a synthetic
      progestin that does not have any androgenic and estrogenic activity and is not expected to
      have some of the undesirable side effects of other drugs.

      We propose to evaluate whether NES gel alone or in combination with T gel applied
      transdermally will result in more effective suppression of gonadotropins than NES or T gel
      applied alone in healthy men. Fifty healthy male subjects, age 18-50 will be enrolled at each
      center (2 sites).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">January 2007</completion_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>- To determine the gonadotropin suppressive activity of Nestorone (NES) Gel at two doses and T gel at one dose alone or in combination over a 3-week period. Serum levels of gonadotropins will be assessed in all subjects.</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the effects on serum levels of total and free testosterone and SHBG and measure serum levels of NES gel.</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety measured laboratory evaluations, vitals, pre- and post treatment physical exam results and PSA levels</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>100 mg Testosterone gel daily for 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 mg Nestorone gel daily for 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4 mg Nestorone gel daily for 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>100 mg Testosterone gel + 2 mg Nestorone gel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>100 mg Testosterone gel + 4 mg Nestorone gel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>100 mg Testosterone Gel + 6 mg Nestorone Gel daily for 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>100 mg Testosterone Gel + 8 mg Nestorone gel daily for 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nestorone gel</intervention_name>
    <description>2 to 8 mg Nestorone gel daily for 3 weeks depending on treatment group assignment</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
    <arm_group_label>6</arm_group_label>
    <arm_group_label>7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone Gel</intervention_name>
    <description>100 mg Testosterone gel daily for 3 weeks</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
    <arm_group_label>6</arm_group_label>
    <arm_group_label>7</arm_group_label>
    <other_name>Testim</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy men

          -  Aged 18-50 years

          -  With normal clinical chemistry, serum levels of testosterone, PSA, gonadotropins
             within normal limits, and sperm concentration greater than 20 million/mL

          -  Subject or his partner willing to use a recognized effective method of contraception

        Exclusion Criteria:

          -  Men not living in area of clinics

          -  Clinically significant abnormal findings at screening

          -  Elevated PSA greater than 4

          -  Partners who are pregnant

          -  Abnormal laboratory values, liver or kidney dysfunction

          -  Sperm counts below 20 million/mL.

          -  Use of androgens or body building substances within 6 months of enrollment,

          -  Blood pressure greater than 140/90, history of hypertension, including hypertension
             controlled with treatment

          -  History of primary testicular disease or disorder of the hypothalamic-pituitary axis

          -  Hypersensitivity of progestins

          -  History of venous thromboembolism

          -  Benign or malignant liver tumors

          -  Active liver disease, history of reproductive dysfunction including vasectomy or
             infertility

          -  History of active or chronic cardiac, renal, hepatic or prostatic disease

          -  Diabetes mellitus or morbid obesity (body weight greater than 120% of ideal body
             weight)

          -  Known or suspected alcoholism or drug abuse

          -  Known dermatitis or severe skin disorder

        Men desiring fertility within 6 months or participating in competitive sports where drug
        screening for prohibited substances (including anabolic steroids) is routine will be
        advised of the relative and temporary hazards that participating in this study may have for
        their fertility or sporting status.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William J Bremner, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christina Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Harbor-UCLA Medical Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://depts.washington.edu/popctr/</url>
    <description>http://depts.washington.edu/popctr/</description>
  </link>
  <link>
    <url>http://www.labiomed.org</url>
    <description>http://www.labiomed.org</description>
  </link>
  <reference>
    <citation>Anawalt BD, Bebb RA, Bremner WJ, Matsumoto AM. A lower dosage levonorgestrel and testosterone combination effectively suppresses spermatogenesis and circulating gonadotropin levels with fewer metabolic effects than higher dosage combinations. J Androl. 1999 May-Jun;20(3):407-14.</citation>
    <PMID>10386821</PMID>
  </reference>
  <reference>
    <citation>Anderson RA, Kinniburgh D, Baird DT. Suppression of spermatogenesis by etonogestrel implants with depot testosterone: potential for long-acting male contraception. J Clin Endocrinol Metab. 2002 Aug;87(8):3640-9.</citation>
    <PMID>12161488</PMID>
  </reference>
  <reference>
    <citation>Bebb RA, Anawalt BD, Christensen RB, Paulsen CA, Bremner WJ, Matsumoto AM. Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach. J Clin Endocrinol Metab. 1996 Feb;81(2):757-62.</citation>
    <PMID>8636300</PMID>
  </reference>
  <reference>
    <citation>Brache V, Massai R, Mishell DR, Moo-Young AJ, Alvarez F, Salvatierra AM, Cochon L, Croxatto H, Robbins A, Faundes A. Ovarian function during use of Nestorone(R) subdermal implants. Contraception. 2000 Mar;61(3):199-204.</citation>
    <PMID>10827334</PMID>
  </reference>
  <reference>
    <citation>Cummings DE, Bremner WJ. Prospects for new hormonal male contraceptives. Endocrinol Metab Clin North Am. 1994 Dec;23(4):893-922. Review.</citation>
    <PMID>7705326</PMID>
  </reference>
  <reference>
    <citation>Díaz S, Schiappacasse V, Pavez M, Zepeda A, Moo-Young AJ, Brandeis A, Lähteenmäki P, Croxatto HB. Clinical trial with Nestorone subdermal contraceptive implants. Contraception. 1995 Jan;51(1):33-8.</citation>
    <PMID>7750282</PMID>
  </reference>
  <reference>
    <citation>Gonzalo IT, Swerdloff RS, Nelson AL, Clevenger B, Garcia R, Berman N, Wang C. Levonorgestrel implants (Norplant II) for male contraception clinical trials: combination with transdermal and injectable testosterone. J Clin Endocrinol Metab. 2002 Aug;87(8):3562-72.</citation>
    <PMID>12161475</PMID>
  </reference>
  <reference>
    <citation>Haukkamaa M, Laurikka-Routti M, Heikinheimo O, Moo-Young A. Contraception with subdermal implants releasing the progestin ST-1435: a dose-finding study. Contraception. 1992 Jan;45(1):49-55.</citation>
    <PMID>1591921</PMID>
  </reference>
  <reference>
    <citation>Handelsman DJ, Conway AJ, Howe CJ, Turner L, Mackey MA. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot. J Clin Endocrinol Metab. 1996 Nov;81(11):4113-21.</citation>
    <PMID>8923869</PMID>
  </reference>
  <reference>
    <citation>Kamischke A, Heuermann T, Krüger K, von Eckardstein S, Schellschmidt I, Rübig A, Nieschlag E. An effective hormonal male contraceptive using testosterone undecanoate with oral or injectable norethisterone preparations. J Clin Endocrinol Metab. 2002 Feb;87(2):530-9.</citation>
    <PMID>11836281</PMID>
  </reference>
  <reference>
    <citation>Kamischke A, Venherm S, Plöger D, von Eckardstein S, Nieschlag E. Intramuscular testosterone undecanoate and norethisterone enanthate in a clinical trial for male contraception. J Clin Endocrinol Metab. 2001 Jan;86(1):303-9.</citation>
    <PMID>11232016</PMID>
  </reference>
  <results_reference>
    <citation>Mahabadi V, Amory JK, Swerdloff RS, Bremner WJ, Page ST, Sitruk-Ware R, Christensen PD, Kumar N, Tsong YY, Blithe D, Wang C. Combined transdermal testosterone gel and the progestin nestorone suppresses serum gonadotropins in men. J Clin Endocrinol Metab. 2009 Jul;94(7):2313-20. doi: 10.1210/jc.2008-2604. Epub 2009 Apr 14.</citation>
    <PMID>19366848</PMID>
  </results_reference>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 27, 2005</study_first_submitted>
  <study_first_submitted_qc>September 27, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2005</study_first_posted>
  <last_update_submitted>December 3, 2014</last_update_submitted>
  <last_update_submitted_qc>December 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>William Bremner</investigator_full_name>
    <investigator_title>Study Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Male contraception</keyword>
  <keyword>Androgen</keyword>
  <keyword>Progestin</keyword>
  <keyword>Spermatogenesis</keyword>
  <keyword>Gonadotropin suppression</keyword>
  <keyword>Testosterone</keyword>
  <keyword>Nestorone</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>ST 1435</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

